MEDEXIS is a biotechnology company that identifies, develops and commercializes new life science technologies. A special focus of the company is to foster products to detect or treat human disease.

Founded in 2002, Medexis is a proud member of the Gerolymatos Group of Companies (P.N.G.) based in Athens, Greece. P.N.G. is one of the largest privately held pharmaceuticals in the Mediterranean region with an impressive track record in the development and sale of a wide range of health care products.

MEDEXIS has a growing portfolio of therapeutic and diagnostic projects that address unmet needs in oncology and other areas. One drug candidate (MDX-12C) is in pre-clinical development for the treatment of prostate cancer. The company expects to launch a PCR-based test for cancer (Medexis CK-19 Quantification Kit) within Q3 2008.

MEDEXIS works closely with individual scientists, corporations and academic institutions throughout Europe and the United States. The company is based in Athens (Kryoneri), Greece.